Innoupfarma

InnoUp is a clinical-stage nanotechnology company focused on developing safer and more effective treatments for Food Allergies, Oncology, and Vaccines. We have developed a new drug encapsulation platform currently being tested in different clinical and pre-clinical programs. INP20 - Oral Peanut Allergy Vaccine: Phase I INP12 - Low-toxicity Paclitaxel oral chemotherapy for Breast Cancer: Phase I INP30 - Oral Vaccine Infectious Diseases: pre-clinical Our encapsulation platform is based on biocompatible nanoparticles that allow all types of payloads (drugs, proteins, RNA, and DNA). These nanoparticles have been engineered to increase bio-adhesion capacity to the mucosa, which translates into a need for lower and safer drug doses to achieve a therapeutic effect. Therefore, drugs encapsulated using our platform become more effective and safer. The technology is protected worldwide, including USA and Europe, until 2035. Our short-term business strategy includes starting operations in the US beginning 2022 with the opening of an affiliate in Boston, MA. From there, we will manage the movement to the next phases of our clinical programs (Phase II) in the US. We are already working with the FDA for the pre-IND meeting preparation. We plan to increase our value in the mid-term by building a clinical-stage multi-asset pipeline with expected significant efficacy and safety milestones by 2025. Besides, we plan to build our GMP manufacturing facility to control our manufacturing process fully. We expect it to be fully operative by 2025. We are actively working on raising money to cover the following steps and, we are open to considering all types of investment. In parallel, we are also actively seeking licensing partners interested in our products.